Perceptive Advisors LLC Increases Stake in Amylyx Pharmaceuticals to 7.5%

Perceptive Advisors LLC, along with Joseph Edelman and the Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Amylyx Pharmaceuticals, Inc. (AMLX). The filing indicates that the reporting persons collectively own 8,284,882 shares of common stock, representing a 7.5% ownership stake in the company. This position is held directly by the Perceptive Life Sciences Master Fund, Ltd., with Perceptive Advisors LLC serving as the investment manager and Joseph Edelman acting as the managing member. The filing is an amendment to a previous schedule, marking an increase from a previously reported 0% position, as per the supplemental data provided. The ownership calculation is based on 111,186,317 shares outstanding as of April 27, 2026. The reporting persons have certified that these shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.